

Clare Arnott

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2093672/publications.pdf>

Version: 2024-02-01

61
papers

2,693
citations

304743

22
h-index

197818

49
g-index

61
all docs

61
docs citations

61
times ranked

3620
citing authors

#	ARTICLE	IF	CITATIONS
1	SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 845-854.	11.4	595
2	Sex differences in heart failure. <i>European Heart Journal</i> , 2019, 40, 3859-3868c.	2.2	406
3	Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 305-316.	5.3	188
4	Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2020, 9, e014908.	3.7	161
5	Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data. <i>Lancet, The</i> , 2021, 397, 1085-1094.	13.7	146
6	Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. <i>Circulation</i> , 2022, 145, 1460-1470.	1.6	97
7	Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. <i>European Heart Journal</i> , 2021, 42, 4891-4901.	2.2	80
8	Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. <i>Kidney International</i> , 2020, 98, 769-777.	5.2	69
9	Sex Differences in Primary and Secondary Prevention of Cardiovascular Disease in China. <i>Circulation</i> , 2020, 141, 530-539.	1.6	62
10	Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease. <i>Circulation</i> , 2021, 143, 1735-1749.	1.6	60
11	Prognostic Value of Secreted Frizzled-Related Protein 5 in Heart Failure Patients With and Without Type 2 Diabetes Mellitus. <i>Circulation: Heart Failure</i> , 2020, 13, e007054.	3.9	46
12	Maternal cardiovascular risk after hypertensive disorder of pregnancy. <i>Heart</i> , 2020, 106, 1927-1933.	2.9	45
13	Cardiovascular Disease in Women: From Pathophysiology to Novel and Emerging Risk Factors. <i>Heart Lung and Circulation</i> , 2021, 30, 9-17.	0.4	45
14	Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial. <i>Diabetologia</i> , 2021, 64, 2147-2158.	6.3	45
15	Prognosis of unrecognised myocardial infarction determined by electrocardiography or cardiac magnetic resonance imaging: systematic review and meta-analysis. <i>BMJ, The</i> , 2020, 369, m1184.	6.0	43
16	<scp>Sodium-glucose cotransporter 2</scp> inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 382-390.	4.4	40
17	Colchicine in Cardiovascular Disease: In-Depth Review.. <i>Circulation</i> , 2022, 145, 61-78.	1.6	37
18	A Systematic Review of Vascular Structure and Function in Pre-eclampsia: Non-invasive Assessment and Mechanistic Links. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 166.	2.4	36

#	ARTICLE	IF	CITATIONS
19	Effects of a reduced-sodium added-potassium salt substitute on blood pressure in rural Indian hypertensive patients: a randomized, double-blind, controlled trial. <i>American Journal of Clinical Nutrition</i> , 2021, 114, 185-193.	4.7	36
20	Subtle increases in heart size persist into adulthood in growth restricted babies: the Cardiovascular Risk in Young Finns Study. <i>Open Heart</i> , 2015, 2, e000265.	2.3	34
21	Colchicine as a Novel Therapy for Suppressing Chemokine Production in Patients With an Acute Coronary Syndrome: A Pilot Study. <i>Clinical Therapeutics</i> , 2019, 41, 2172-2181.	2.5	33
22	The effect of canagliflozin on amputation risk in the <scp>CANVAS</scp> program and the <scp>CRENDENCE</scp> trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1753-1766.	4.4	31
23	The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial Cells. <i>PLoS ONE</i> , 2016, 11, e0150688.	2.5	24
24	Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the <scp>CANVAS</scp> Program and <scp>CRENDENCE</scp> trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1072-1083.	4.4	20
25	Pulmonary vasodilator therapy is associated with greater survival in Eisenmenger syndrome. <i>Heart</i> , 2018, 104, 732-737.	2.9	19
26	The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. <i>International Journal of Cardiology</i> , 2020, 318, 126-129.	1.7	18
27	Women and Cardiovascular Disease: Pregnancy, the Forgotten Risk Factor. <i>Heart Lung and Circulation</i> , 2020, 29, 662-667.	0.4	17
28	Blood pressure postpartum (BP2) RCT protocol: Follow-up and lifestyle behaviour change strategies in the first 12 months after hypertensive pregnancy. <i>Pregnancy Hypertension</i> , 2020, 22, 1-6.	1.4	16
29	Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program. <i>ESC Heart Failure</i> , 2021, 8, 1482-1493.	3.1	16
30	Association Between Circulating GDFâ€15 and Cardioâ€Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e021661.	3.7	16
31	Heart Failure with Reduced Ejection Fractionâ€”Does Sex Matter?. <i>Current Heart Failure Reports</i> , 2021, 18, 345-352.	3.3	15
32	Sex Disparities in Sudden Cardiac Death. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009834.	4.8	14
33	Assessing knowledge of healthcare providers concerning cardiovascular risk after hypertensive disorders of pregnancy: an Australian national survey. <i>BMC Pregnancy and Childbirth</i> , 2020, 20, 717.	2.4	13
34	Effects of canagliflozin on myocardial infarction: a <i>post hoc</i> analysis of the CANVAS programme and CRENDENCE trial. <i>Cardiovascular Research</i> , 2022, 118, 1103-1114.	3.8	13
35	Sodiumâ€glucose coâ€transporterâ€2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and metaâ€analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 252-257.	4.4	12
36	Rationale, design, and baseline characteristics of the Salt Substitute in India Study (SSiS): The protocol for a doubleâ€blinded, randomizedâ€controlled trial. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1504-1512.	2.0	11

#	ARTICLE	IF	CITATIONS
37	Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1950-1956.	4.4	11
38	Quantifying right atrial filling and emptying: A 4D-flow MRI study. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 45, 1046-1054.	3.4	10
39	Guideline-Directed Medical Therapy in Females with Heart Failure with Reduced Ejection Fraction. <i>Current Heart Failure Reports</i> , 2021, 18, 284-289.	3.3	10
40	Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1927-1938.	4.4	10
41	A Case of ST Elevation Myocardial Infarction Secondary to Heparin-induced Thrombocytopenia with Thrombosis. <i>Heart Lung and Circulation</i> , 2012, 21, 841-843.	0.4	8
42	Pulmonary Vein Isolation Compared to Rate Control in Patients with Atrial Fibrillation: A Systematic Review and Meta-analysis. <i>Heart Lung and Circulation</i> , 2015, 24, 744-752.	0.4	8
43	The long-term cardiovascular impact of hypertension in pregnancy – A missed opportunity. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2021, 61, 474-477.	1.0	8
44	Paradoxical Cardiac and Cerebral Arterial Gas Embolus During Percutaneous Lead Extraction in a Patient with a Patent Foramen Ovale. <i>Heart Lung and Circulation</i> , 2015, 24, e14-e17.	0.4	7
45	The Role of Sodium Glucose Cotransporter-2 Inhibitors in Atherosclerotic Cardiovascular Disease: A Narrative Review of Potential Mechanisms. <i>Cells</i> , 2021, 10, 2699.	4.1	7
46	Optimising mothers' health behaviour after hypertensive disorders of pregnancy: a qualitative study of a postnatal intervention. <i>BMC Public Health</i> , 2022, 22, .	2.9	7
47	Survival outcomes in severe congenital versus non-congenital pulmonary hypertension. <i>Heart Asia</i> , 2016, 8, 3-7.	1.1	6
48	An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials. <i>International Journal of Cardiology</i> , 2021, 324, 165-172.	1.7	6
49	The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1652-1659.	4.4	6
50	Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program. <i>Diabetologia</i> , 2021, 64, 2402-2414.	6.3	6
51	Comparative Efficacy and Safety of BP-Lowering Pharmacotherapy in Patients Undergoing Maintenance Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1129-1138.	4.5	5
52	The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial. <i>Diabetes and Metabolism</i> , 2022, 48, 101331.	2.9	5
53	Characterisation of novel cytokines in human atherosclerotic plaque. <i>International Journal of Cardiology</i> , 2014, 176, 1167-1169.	1.7	4
54	Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial. <i>Journal of Diabetes Research</i> , 2022, 2022, 1-12.	2.3	3

#	ARTICLE	IF	CITATIONS
55	Procedural Volumes in the Era of COVID: The Risk Versus Benefit Trade-Off. Heart Lung and Circulation, 2021, 30, 1430-1432.	0.4	2
56	The Echocardiographic Characteristics and Prognostic Significance of Pericardial Effusions in Eisenmenger Syndrome. Heart Lung and Circulation, 2018, 27, 394-396.	0.4	1
57	Do GLP-1 Receptor Agonists Care if You Have Heart Failure?. Circulation, 2019, 140, 1623-1625.	1.6	1
58	Tackling Disparities in Heart Care and Disease Outcomes in Women: Insights and Highlights From the Women and Heart Disease Forum. Heart Lung and Circulation, 2019, 28, 1449-1451.	0.4	1
59	A Novel Cardioprotective Therapy That Also Improves Glycemia. JAMA - Journal of the American Medical Association, 2020, 323, 1349.	7.4	1
60	Why Are We Forgetting Patients With Peripheral Arterial Disease?. Heart Lung and Circulation, 2021, 30, 939-942.	0.4	1
61	Association of Baseline Diuretic Use With Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: A Secondary Analysis From TOPCAT. Journal of Cardiac Failure, 2021, 27, 816-818.	1.7	0